Search results
Cannabis and/or cannabinoid access and use by adults with cancer has outpaced the science supporting their clinical use. This guideline provides strategies for open, nonjudgmental communication between clinicians and adults with cancer about the use of cannabis and/or cannabinoids.
- Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline Q&A
Adults with cancer new to oral cannabis and/or cannabinoid...
- Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline Q&A
20 maj 2022 · The results of this study suggest that MC treatment is generally safe for oncology patients and can potentially reduce the burden of associated symptoms with no serious MC-related adverse effects. Keywords: medical use, cannabis, phytocannabinoids, oncology, cancer, prospective. Introduction.
13 mar 2024 · Adults with cancer new to oral cannabis and/or cannabinoid products should recognize that the onset of action may be >1 hour and cautioned to avoid stacking doses, which could lead to side effects as mentioned above (eg, dizziness, confusion, fatigue, paranoia, tachycardia, orthostatic hypotension). 10, 11.
27 mar 2023 · Objectives: Describe the pharmacodynamics of medical marijuana. Identify the active compounds within the cannabis plant that hold potential therapeutic benefits within the field of oncology. Outline the potential adverse events a patient may experience while consuming medical marijuana.
28 lis 2021 · This conference report from the National Cancer Institute's "Cannabis, Cannabinoid and Cancer Research Symposium" on the topic of "Cancer Symptom/Treatment Side Effect Management" is an expert perspective of cannabis intervention for cancer and cancer treatment-related symptoms.
10 lut 2022 · In this article, we explore some of the potential mechanisms of action of CBD in cancer, and evidence of its efficacy in the integrative management of cancer including the side effects associated with its treatment, demonstrating its potential for integration with orthodox cancer care.
28 lis 2021 · The following monograph highlights recent preclinical research focusing on promising cannabinoid-based approaches for the treatment of the 2 most common adverse effects of cancer chemotherapy: chemotherapy-induced peripheral neuropathy and chemotherapy-induced nausea and vomiting.
